Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting (VeRVe)

AbbVie

Status: Enrolling

Conditions: Chronic Lymphocytic Leukemia (CLL)

Study type: Observational

Funder types: Industry

Identifiers

NCT03342144

P17-132

Details and patient eligibility

About

An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment.

Exclusion criteria

- None

Trial design

500 participants in 5 patient groups

Participants Receiving Venetoclax

Description:

Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.

Participants Receiving Venetoclax + Rituximab

Description:

Participants with CLL receiving venetoclax in combination with rituximab.

Participants Receiving Venetoclax + Obinutuzumab

Description:

Participants with CLL receiving venetoclax in combination with obinutuzumab.

Participants Receiving Venetoclax + Ibrutinib

Description:

Participants with CLL receiving venetoclax in combination with ibrutinib.

Participants Receiving Venetoclax + Acalabrutinib

Description:

Participants with CLL receiving venetoclax in combination with acalabrutinib.